{"id":386088,"date":"2021-11-30T00:00:00","date_gmt":"2021-11-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/m360va0032-medtech-vascular-access-devices-market-insights-europe-2022\/"},"modified":"2026-05-07T23:04:20","modified_gmt":"2026-05-07T23:04:20","slug":"m360va0032-medtech-vascular-access-devices-market-insights-europe-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/m360va0032-medtech-vascular-access-devices-market-insights-europe-2022\/","title":{"rendered":"Vascular Access Devices | Market Insights | Europe | 2022"},"content":{"rendered":"<p>Over the forecast period, the European vascular access device market will\u00a0grow at a modest rate. Although\u00a0some segments will experience market contractions, this will be outweighed by\u00a0rapid growth\u00a0in the\u00a0PICC\u00a0segment, which is being driven by an increase in the number of nurses performing these procedures and the development of tip location techniques that make\u00a0PICC\u00a0placement easier. The growth will be supported by rising adoption of new technologies such as power-injectable devices, and devices with antimicrobial coatings. However, market revenues will be hindered to some extent by declining\u00a0ASPs resulting from pricing pressures and increasing competition. Importantly, vascular access devices represent a key component of care for\u00a0COVID-19\u00a0patients, and therefore the pandemic\u2019s impact on procedures, unit sales, and revenues has been incorporated into market projections.<\/p>\n<p>This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for vascular access devices in Europe, with market projections across an 11-year period.<\/p>\n","protected":false},"template":"","class_list":["post-386088","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-vascular-access-devices","medtech-geography-europe","medtech-date-949"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/386088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/386088\/revisions"}],"predecessor-version":[{"id":387597,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/386088\/revisions\/387597"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=386088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}